Paul Brannelly

Paul Brannelly has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Sirtris Pharmaceuticals, Inc., Collegium Pharmaceutical, Inc and Karyopharm Therapeutics Inc. We count 93 filings; the first trade dates from 2 January 2008 and the latest from 10 February 2021.

In open-market terms, that means 4 purchases worth €134k on one side and 49 sales worth €353k on the other. Netting one side against the other leaves €219k of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 38 share grants and 1 option exercise.

Half of the purchases are above €18k and half below. Ninety days after publication, 4 purchases show a median change of +44.0%, with the price up in 100% of them. These figures describe past trades and do not predict future prices.

On 12 February 2021 came the latest disclosure, a share grant for €55k in Collegium Pharmaceutical, Inc. The last insider purchase was made public on 15 May 2017, 3,449 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.